Recolony Insights

Recolony is a spin-off company from the University of Zurich that started as a research project in the Department of Gastroenterology and Hepatology at the University Hospital Zurich. The investigation of the effect of certain commensal bacteria on the anti-cancer immune response led to impressive results and to the decision to translate these findings to a clinical application. With this mission, Recolony became part of the Wyss Zurich Translational Center, a joint accelerator of the University of Zurich and ETH Zurich. 

Our incentive is to provide high-quality therapy to cancer patients, with the aim to maximize treatment efficacy and at the same time the quality of life of the people suffering from this life-changing disease. For that purpose, we invest our efforts in high-class research to produce new, innovative therapies that ultimately bring the desired benefits to the patients.